NASDAQ: CADL
Candel Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CADL

Based on 5 analysts offering 12 month price targets for Candel Therapeutics Inc

Min Forecast
$7.00+10.24%
Avg Forecast
$18.40+189.76%
Max Forecast
$24.00+277.95%

Should I buy or sell CADL stock?

Based on 5 analysts offering ratings for Candel Therapeutics Inc.

Buy
Strong Buy
2 analysts 40%
Buy
2 analysts 40%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CADL's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CADL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CADL stock forecasts and price targets.

CADL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-08
lockedlocked$00.00+00.00%2025-11-14
lockedlocked$00.00+00.00%2025-10-21
lockedlocked$00.00+00.00%2025-09-29
lockedlocked$00.00+00.00%2025-09-03
HC Wainwright & Co.
Top 1%
100
BuyAssumes$23.00+262.20%2025-06-30

1 of 1

Forecast return on equity

Is CADL forecast to generate an efficient return?

Company
N/A
Industry
252.48%
Market
228.08%

Forecast return on assets

Is CADL forecast to generate an efficient return on assets?

Company
N/A
Industry
90.65%

CADL earnings per share forecast

What is CADL's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.42
Avg 2 year Forecast
-$1.01
Avg 3 year Forecast
-$0.48

CADL revenue forecast

What is CADL's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$59.2M

CADL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CADL$6.35$18.40+189.76%Buy
NMRA$2.09$7.40+254.07%Buy
LRMR$4.05$16.60+309.88%Buy
MREO$2.17$6.50+199.54%Strong Buy
NBY$2.80N/AN/A

Candel Therapeutics Stock Forecast FAQ

Is Candel Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CADL) stock is to Buy CADL stock.

Out of 5 analysts, 2 (40%) are recommending CADL as a Strong Buy, 2 (40%) are recommending CADL as a Buy, 1 (20%) are recommending CADL as a Hold, 0 (0%) are recommending CADL as a Sell, and 0 (0%) are recommending CADL as a Strong Sell.

If you're new to stock investing, here's how to buy Candel Therapeutics stock.

What is CADL's earnings growth forecast for 2025-2027?

(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.

Candel Therapeutics's earnings in 2025 is -$22,759,000.On average, 9 Wall Street analysts forecast CADL's earnings for 2025 to be -$23,320,799, with the lowest CADL earnings forecast at -$23,134,145, and the highest CADL earnings forecast at -$23,633,719. On average, 8 Wall Street analysts forecast CADL's earnings for 2026 to be -$55,568,062, with the lowest CADL earnings forecast at -$78,762,595, and the highest CADL earnings forecast at -$28,821,609.

In 2027, CADL is forecast to generate -$26,219,430 in earnings, with the lowest earnings forecast at -$60,794,381 and the highest earnings forecast at $40,926,685.

What is CADL's revenue growth forecast for 2025-2027?

(NASDAQ: CADL) Candel Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.

Candel Therapeutics's revenue in 2025 is $0.On average, 8 Wall Street analysts forecast CADL's revenue for 2025 to be $0, with the lowest CADL revenue forecast at $0, and the highest CADL revenue forecast at $0. On average, 8 Wall Street analysts forecast CADL's revenue for 2026 to be $0, with the lowest CADL revenue forecast at $0, and the highest CADL revenue forecast at $0.

In 2027, CADL is forecast to generate $3,247,509,114 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $9,298,125,579.

What is CADL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CADL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 90.65%.

What is CADL's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CADL price target, the average CADL price target is $18.40, with the highest CADL stock price forecast at $24.00 and the lowest CADL stock price forecast at $7.00.

On average, Wall Street analysts predict that Candel Therapeutics's share price could reach $18.40 by Dec 8, 2026. The average Candel Therapeutics stock price prediction forecasts a potential upside of 189.76% from the current CADL share price of $6.35.

What is CADL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CADL) Candel Therapeutics's current Earnings Per Share (EPS) is -$0.54. On average, analysts forecast that CADL's EPS will be -$0.42 for 2025, with the lowest EPS forecast at -$0.42, and the highest EPS forecast at -$0.43. On average, analysts forecast that CADL's EPS will be -$1.01 for 2026, with the lowest EPS forecast at -$1.43, and the highest EPS forecast at -$0.53. In 2027, CADL's EPS is forecast to hit -$0.48 (min: -$1.11, max: $0.75).

What is CADL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CADL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.